Symbols

NSPR

InspireMD·NASDAQ

--(--)

NSPR fundamentals

NSPR Q4 2025 Earnings

InspireMD (NSPR) released its earnings on Mar 18, 2026: revenue was 3.15M (YoY +61.57%), beat estimates; EPS was -0.14 (YoY +26.32%), beat estimates.

Revenue / YoY

3.15M

+61.57%

EPS / YoY

-0.14

+26.32%

Report date

Mar 18, 2026

NSPR Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 62% YoY to $3.1 million, driven by U.S. CGuard Prime launch.
U.S. Momentum: 500+ cases completed, 200+ centers in pipeline, 70% gross margin.
2026 Outlook: $13-15 million revenue (45-65% growth), H2 acceleration with TCAR approval.
Clinical Progress: C-GUARDIANS II data in April, TCAR indication Q3, enhanced delivery system Q4.

Earnings

EPS

Revenue

Revenue & Expenses

NSPR has released its 2025 Q4 earnings report, with revenue of 3.15M, reflecting a YoY change of 61.57%, and net profit of -11.76M, showing a YoY change of -28.20%. The Sankey diagram below clearly presents NSPR's revenue sources and cost distribution.

Key Indicators

InspireMD (NSPR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

InspireMD (NSPR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

InspireMD (NSPR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

InspireMD (NSPR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown